CXCR3 and neoplasm: Mice were implanted with KPC-derived tumor cells on a single flank, and then treated with a STING agonist, which significantly reduced the tumor burden, increased the CD8+/CD4+ T-cell ratio, and increased CXCR3+ CD8+ T cells in the PDAC TME [125].